# This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis

> **NCT02772601** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 21 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Caffeine
- **DRUG:** Warfarin
- **DRUG:** Omeprazole
- **DRUG:** Metoprolol
- **DRUG:** Midazolam
- **DRUG:** Risankizumab

## Key facts

- **NCT ID:** NCT02772601
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-15
- **Primary completion:** 2017-06-15
- **Final completion:** 2017-09-22
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2017-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02772601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02772601, "This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02772601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*